ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Galectin Therapeutics Inc

Galectin Therapeutics Inc (GALT)

2.42
-0.09
(-3.59%)
Closed July 19 4:00PM
2.42
0.00
( 0.00% )
Pre Market: 4:00AM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
2.42
Bid
2.00
Ask
3.00
Volume
-
0.00 Day's Range 0.00
1.35 52 Week Range 4.2684
Market Cap
Previous Close
2.42
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
192,743
Shares Outstanding
62,148,134
Dividend Yield
-
PE Ratio
-3.36
Earnings Per Share (EPS)
-0.72
Revenue
-
Net Profit
-44.81M

About Galectin Therapeutics Inc

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in prec... Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Carson City, Nevada, USA
Founded
1970
Galectin Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GALT. The last closing price for Galectin Therapeutics was $2.42. Over the last year, Galectin Therapeutics shares have traded in a share price range of $ 1.35 to $ 4.2684.

Galectin Therapeutics currently has 62,148,134 shares outstanding. The market capitalization of Galectin Therapeutics is $150.40 million. Galectin Therapeutics has a price to earnings ratio (PE ratio) of -3.36.

GALT Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.156.607929515422.272.922.241556022.48390168CS
40.093.862660944212.332.9222987392.26558507CS
12-0.97-28.61356932153.393.7821927432.60856314CS
260.6435.95505617981.784.26841.591671162.78751424CS
520.8251.251.64.26841.351120922.54067168CS
156-0.41-14.48763250882.834.26841.021250992.47001549CS
260-1.58-39.545.71.023926252.97907423CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SERVServe Robotics Inc
$ 12.46
(65.03%)
10.91M
NCPLNetcapital Inc
$ 0.1452
(39.62%)
15.82M
CISOCISO Global Inc
$ 0.774
(30.08%)
1.13M
RRRichtech Robotics Inc
$ 1.89
(28.57%)
5.61M
NUZENuZee Inc
$ 1.35
(18.54%)
617
XCURExicure Inc
$ 0.4018
(-24.91%)
117.06k
VVOSVivos Therapeutics Inc
$ 2.05
(-16.33%)
1
SNTGSentage Holdings Inc
$ 2.09
(-15.73%)
5.6k
NVOSNovo Integrated Sciences Inc
$ 0.5668
(-14.77%)
108.6k
SNOASonoma Pharmaceuticals Inc
$ 0.265
(-13.96%)
540
NCPLNetcapital Inc
$ 0.1452
(39.62%)
15.82M
SERVServe Robotics Inc
$ 12.46
(65.03%)
10.91M
RRRichtech Robotics Inc
$ 1.89
(28.57%)
5.61M
MAXNMaxeon Solar Technologies Ltd
$ 0.221
(2.50%)
1.8M
SQQQProShares UltraPro Short QQQ
$ 8.27
(-2.25%)
1.75M

GALT Discussion

View Posts
Retire43 Retire43 4 weeks ago
https://www.globenewswire.com/news-release/2024/06/27/2905450/0/en/Bioxytran-s-Advisor-Releases-Book-on-Hyperbaric-Oxygenation-Related-to-Stroke-Alzheimer-s-Patients.html
πŸ‘οΈ0
Retire43 Retire43 2 months ago
https://medicaldialogues.in/medicine/news/galectin-3-promising-biomarker-for-predicting-long-covid-among-patients-of-covid-19-study-129158
πŸ‘οΈ0
Retire43 Retire43 2 months ago
Todays emerging growth conference
CEO DAVID PLATT $BIXT
BioxyTran.

https://emerginggrowth.com/emerging-growth-conference-70/

πŸ‘οΈ0
Retire43 Retire43 3 months ago
https://www.nasdaq.com/press-release/6-stocks-positioned-to-soar-as-investors-focus-on-mash-2024-04-22
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
Reached a peak.
πŸ‘οΈ0
vein vein 3 months ago
Letting some air out today !!
πŸ‘οΈ0
vein vein 3 months ago
But I had 20,000 !!!
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 3 months ago
AND AT 2.45...YA GOT ME BEAT BIG TIME!
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 3 months ago
ONLY...LOL...I ONLY HAVE A 1000..NICE WORK CHAMP!!
πŸ‘οΈ0
vein vein 3 months ago
Man , I only bought 5000 shares at 1.20 . Happy but I should have loaded the boat a bit more.
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 3 months ago
GALT...THESE BIO BEAST OF THE BIO MARKET
πŸ‘οΈ0
Retire43 Retire43 3 months ago
https://www.insiderfinancial.com/post/galectin-therapeutics-galt-a-discount-opportunity-moving-on-analysts-upgrade
πŸ‘οΈ0
Retire43 Retire43 3 months ago
Hey look at this;
GALT shareholders!
If you want an alternative to or additionally own a Galectin drug by the creator of Galectin antagonist, Dr Platt the father of the new science glycovirlogy

Viruses
Cancer
And hypoxia drug! BXT 25

https://www.insiderfinancial.com/post/galectin-therapeutics-galt-a-discount-opportunity-moving-on-analysts-upgrade
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 3 months ago
GALT..THE BIO BEAST THAT KEEPS BEASTING...
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 3 months ago
GALT the bio beast of the bio techs
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
GALT new 52 hi
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 3 months ago
GALT BREAKING OUT
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 4 months ago
Play the chart not the story and sell before news
πŸ‘οΈ0
vein vein 4 months ago
What do we think this run is credited to ?? Our data readout isn’t until Q4??
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 4 months ago
GALT WEEKLY BREAK OUT HERE IS STRONG
πŸ‘οΈ0
Monksdream Monksdream 4 months ago
GALT new 52 hi
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 4 months ago
GALT BIO BEAST!!!
πŸ‘οΈ0
vein vein 4 months ago
Just trying to justify the run here. I’m happy of course , my entry was 1.20
πŸ‘οΈ0
Monksdream Monksdream 4 months ago
So sell short
πŸ‘οΈ0
vein vein 4 months ago
With no news , trial results not for a long time
πŸ‘οΈ0
Monksdream Monksdream 4 months ago
GALT new 52 hi
πŸ‘οΈ0
vein vein 4 months ago
Hmmm could be
πŸ‘οΈ0
Monksdream Monksdream 4 months ago
Professional asset manager support
πŸ‘οΈ0
vein vein 4 months ago
Wonder why we have such positive movement here ???
πŸ‘οΈ0
Monksdream Monksdream 4 months ago
GALT under $3
πŸ‘οΈ0
Glycobio Glycobio 9 months ago
In any case, setting aside the noise, the most important thing is that this is the only drug candidate in a late stage clinical trial which has the potential to address a fatal complication of NASH cirrhosis. The excess galectin-3 in the disease process increases fibrotic activity and portal hypertension. GALT's galectin-3 inhibitor, belapectin, is a large chain carbohydrate compound that has side chains that are similar to the natural galectin-3 ligand, and inhibits the excess galectin-3 produced by macrophages in the liver. Since the body can metabolize this carbohydrate compound without relying on the liver, it does not put extra strain on the liver, which is why they had good results recently from the 4th data safety monitoring board (unlike competitors who keep running into safety issues with their liver drugs). When this galectin-3 pathway disease process is kept in check, it stabilizes portal hypertension, with the goal of reducing the formation of esophageal varices that develop from excess portal hypertension. Many cirrhosis patients die from bleeding varices. GALT could potentially offer a breakthrough treatment for the subgroup of patients who have not developed varices yet, by repeating prior phase 2 results in this phase 2/3 adaptive trial. As an investment it is very interesting because the stock price is so low right now compared to the risk/reward which I think is pretty good. If successful with the next readout the market cap could jump to billions.

By the way I have zero connection with the company or anyone associated with the company. I have an interest in glycobiology research which is why I study these topics in depth. I randomly came across this inverstorshub board and noticed a lot of misinformation or misguided info here so I figured I'd pitch in with some knowledge.
πŸ‘οΈ0
sunspotter sunspotter 9 months ago
You’re right about Nasdaq. Sorry.

I will edit my post to omit the incorrect statement that GALT is an OTC stock.
πŸ‘οΈ0
Glycobio Glycobio 9 months ago
That is factually false. Not sure where you are getting your information from. GALT has been on NASDAQ for many years now (more than 10 years?) although yes they started small, like many other companies start small back when they were a team of Harvard and Weizmann Institute researchers. How can you hold it against them that they started small more than 10 years ago.

As far as the founder, I think you're referring to Jim who played a role in venture capital financing but otherwise his role has been very limited, especially since 2018 when he had a disagreement with Traber as the CEO he stepped into the background and faded away. And now he was even replaced by Dr. Ben Carson as a board member, so he's not even on the board of directors anymore.

You like to bring up irrelevant things.
πŸ‘οΈ0
sunspotter sunspotter 9 months ago
I posted wrong information so I’ve edited this post.

Still think Ben Carson as a Board Director is the reddest of red flags, though.
πŸ‘οΈ0
Glycobio Glycobio 9 months ago
You're looking at ancient history 20 years ago? The company started with research from Harvard and Weizmann Institute of Science in galectin inhibitors. Employees of the company wrote the authoritative book on Galectins in 2008 (Wiley). Yes they were acting like a startup company in the very beginning which means mistakes, but the drug development is very serious and patients have now started to enter Phase 3 in a global trial for cirrhosis where there are no currently approved drugs yet, which is a major accomplishment to get this far.
πŸ‘οΈ0
sunspotter sunspotter 9 months ago
β€œ Dr. Ben Carson is an advisor and recently joined as a board member. ”

If GALT (previously known as PRWP)’s long history of misrepresentation and failure hasn’t already scared off any thinking person, this appointment should do the trick.
πŸ‘οΈ0
Glycobio Glycobio 9 months ago
This is the only company in a late stage clinical trial for advanced liver disease which as a clinical outcome endpoint (prevention of varices, an often fatal complication). The galectin-3 inhibitor is also showing good results for cancer immunotherapy.

The CEO of GALT takes 80% pay in shares and the Chairman is a multi billionaire financial backer of the company who buys tens of millions in GALT stock periodically.

Dr. Ben Carson is an advisor and recently joined as a board member.

The heavy insider buying is a good sign.
πŸ‘οΈ0
Glycobio Glycobio 9 months ago
There is a lot of spam here from other companies trying to get some attention, that has nothing to do with GALT.
πŸ‘οΈ0
Retire43 Retire43 10 months ago
Look at this reprint! Share this.

https://www.preprints.org/manuscript/202309.0077/v1
πŸ‘οΈ0
sunspotter sunspotter 11 months ago
LOL!

Somewhere in that breathless ridiculous spiel there should be a big disclaimer. I wonder how many free shares it cost?

PRWP may have changed its name and ticker, but it’s still a palpable scam. This leopard never changed its (fraudulent) spots.

Look for the big dump on any volume that absurd pimp piece generates.
πŸ‘οΈ0
Retire43 Retire43 11 months ago
https://www.globenewswire.com/news-release/2023/08/24/2731222/0/en/Bioxytran-Announces-FDA-Clearance-of-its-IND-Application-for-ProLectin-M-in-Clinical-Trials.html
πŸ‘οΈ0
vein vein 1 year ago
Pretty quiet board for a stock that is on the move !!!!!
πŸ‘οΈ0
Retire43 Retire43 1 year ago
Another interview :

https://www.proactiveinvestors.com/companies/news/1005615/bioxytran-drug-candidates-prolectin-m-and-prolectin-i-progressing-as-covid-19-treatments-1005615.html
πŸ‘οΈ0
Retire43 Retire43 1 year ago
WTch this interview about Galectin inhibitors!

https://www.dropbox.com/s/l1d2v2nshekgdj1/bioxytran.mp4?dl=0
πŸ‘οΈ0
vein vein 1 year ago
I got 15000 shares at 1.30. But I wanted more but now don’t want to chase it !!
πŸ‘οΈ0
BIGT80 BIGT80 1 year ago
Hope you started a position! Don’t listen to anyone other than your own DD!
πŸ‘οΈ0
vein vein 1 year ago
Volume is staggering today !!
πŸ‘οΈ0
vein vein 1 year ago
Looks like our CEO got paid in shares again today !!
πŸ‘οΈ0
sunspotter sunspotter 1 year ago
He is a founder of PRWP, GALT’s previous (crooked) incarnation.
πŸ‘οΈ0
BIGT80 BIGT80 1 year ago
Correct he is on the Board of Directors and founder of the 10x fund. The 10x fund does a fair amount of selling throughout the year. Obviously this is small cap bio which comes with with heavy risk. I will however say the current share price is so low it’s kind of an easy swing at a minimum.
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock